MiR-19b also has been reported to accelerate tumor progression and enhance multidrug resistance via loss of PTEN, leading to PI3K/AKT activation and consequently activating multidrug resistance-related genes such as MDR-1, MRP1, and BCRP (Liang et al. 2011; Li et al. 2018). Here, AKT1 is linked to neoplasm.